Table 4 Demographic and Clinical Characteristics of DVT Vs Non-DVT Patients in Direct and Indirect ARDS Cohorts
From: Prevalence, risk, and outcome of deep vein thrombosis in acute respiratory distress syndrome
Characteristics | Direct ARDS (n = 111) | Indirect ARDS (n = 114) | ||||
|---|---|---|---|---|---|---|
DVT (n = 44) | Non-DVT (n = 67) | P Value | DVT (n = 46) | Non-DVT (n = 68) | P value | |
Age (years) | 68 ± 11 | 62 ± 17 | 0.015 | 72 ± 15 | 64 ± 19 | 0.009 |
Male, n (%) | 32 (72.7) | 52 (77.6) | 0.557 | 20 (43.5) | 40 (58.8) | 0.107 |
BMI | 23.5 (20.6, 25.2) | 24.2 (22.2, 27.2) | 0.076 | 24.5 (21.3, 26.8) | 24.0 (22.0, 27.3) | 0.716 |
Bedridden time (days) | 9 (6, 17) | 9 (5, 15) | 0.431 | 10 (4, 19) | 7 (4, 14) | 0.356 |
Caprini score | 7 (5, 8) | 7 (5, 9) | 0.891 | 9 (6, 11) | 7 (5,10) | 0.021 |
Padua prediction score | 5 (5, 6) | 5 (5, 6) | 0.689 | 7 (5, 8) | 6 (4, 7) | 0.008 |
APACHE II score | 22 (17, 26) | 21 (16, 27) | 0.568 | 25 (21, 30) | 25 (19, 32) | 0.913 |
SOFA score | 6 (5, 9) | 6 (4, 10) | 0.780 | 9 (7, 10) | 9 (6,11) | 0.772 |
Laboratory data | ||||||
 White blood cells (×109/L) | 14.5 (10.0, 18.3) | 14.1 (10.2, 20.7) | 0.921 | 18.4 (15.0, 21.5) | 18.1 (13.1, 24.2) | 0.630 |
 Neutrophils (×109/L) | 12.8 (9.1, 16.8) | 12.8 (8.9, 18.0) | 0.935 | 16.1 (13.3, 19.8) | 16.1 (11.0, 21.8) | 0.669 |
 Platelets (× 109/L) | 193.5 (155.3, 279.0) | 181.0 (108.0, 257.0) | 0.301 | 202.0 (84.3, 246.5) | 148.5 (70.8, 234.0) | 0.267 |
 C-reactive protein (mg/L) | 120.0 (82, 120.0) | 120.0 (89.0,120.0) | 0.490 | 120.0 (86.8, 120.0) | 120.0 (94.4, 120.0) | 0.758 |
 Procalcitonin (ng/mL) | 8.3 (2.6, 17.6) | 2.6 (1.1, 9.6) | 0.002 | 15.0 (4.9, 25.0) | 4.9 (2.6, 13.5) | 0.001 |
 Serum creatinine (μmol/L) | 77.3 (56.2, 122.4) | 119.0 (70.6, 225.1) | 0.003 | 135.5 (67.3, 208.8) | 140.7 (70.0, 275.7) | 0.377 |
 D-dimer (μg/ml) | 1.8 (0.7, 3.2) | 1.2 (0.6, 2.1) | 0.211 | 3.2 (1.6, 7.3) | 2.1 (1.3, 4.7) | 0.123 |
 PaO2/FiO2 | 111 (71, 176) | 150 (86, 203) | 0.035* | 152 (117, 184) | 179 (140, 217) | 0.017* |
 Mild, n (%) | 5 (11.4) | 17 (25.4) | 0.062# | 9 (19.6) | 23 (33.8) | 0.249# |
 Moderate, n (%) | 18 (40.9) | 31 (46.3) |  | 30 (65.2) | 37 (54.4) |  |
 Severe, n (%) 21 (47.7) 19 (28.4) 7 (15.2) 8 (11.8) | 21 (47.7) | 19 (28.4) |  | 7 (15.2) | 8 (11.8) |  |
Treatments | ||||||
 Glucocorticoid therapy, n (%) | 16 (36.4) | 15 (22.4) | 0.108 | 6 (13.0) | 14 (20.6) | 0.299 |
 Immunoglobulin, n (%) | 1 (2.3) | 2 (3.0) | 1.000 | 1 (2.2) | 1 (1.5) | 1.000 |
 Sedative therapy, n (%) | 25 (56.8) | 25 (37.3) | 0.043 | 25 (54.3) | 21 (30.9) | 0.012 |
 Vasoactive agent therapy, n (%) | 10 (22.7) | 12 (17.9) | 0.533 | 15 (32.6) | 18 (26.5) | 0.478 |
 CRRT, n (%) | 3 (6.8) | 9 (13.4) | 0.432 | 7 (15.2) | 14 (20.6) | 0.468 |
 CVC, n (%) | 19 (43.2) | 26 (38.8) | 0.646 | 36 (78.3) | 44 (64.7) | 0.121 |
 IMV, n (%) | 34 (77.3) | 31 (46.3) | 0.001 | 32 (69.6) | 25 (36.8) | 0.001 |
 Length of IMV (days) | 3 (2, 6) | 3 (2, 10) | 0.646 | 3 (2, 7) | 3 (2, 8) | 0.586 |
 Length of IMV ≥ 3 days, n (%) | 21 (61.8) | 19 (61.3) | 0.969 | 22 (68.8) | 18 (72.0) | 0.790 |
 Mortality, n (%) | 21 (47.7) | 15 (22.4) | 0.005 | 24 (52.2) | 17 (25.0) | 0.003 |